Sunshine Biopharma (NASDAQ:SBFMW – Get Free Report) is projected to post its results before the market opens on Wednesday, August 5th. Analysts expect Sunshine Biopharma to announce earnings of ($1.20) per share and revenue of $8.70 million for the quarter.
Sunshine Biopharma Stock Performance
Shares of SBFMW opened at $0.03 on Tuesday. The business has a fifty day moving average of $0.05 and a 200 day moving average of $0.11. Sunshine Biopharma has a 52-week low of $0.02 and a 52-week high of $0.65.
About Sunshine Biopharma
Sunshine Biopharma is a development-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics for oncology and antiviral applications. The company’s research activities encompass the design, synthesis and preclinical evaluation of compounds that inhibit key pathways involved in cell proliferation and viral replication.
Among its lead programs, Sunshine Biopharma is advancing Adva-27a, a topoisomerase II inhibitor licensed from the National Research Council of Canada, which is undergoing preclinical studies for potential use in breast and ovarian cancers.
Featured Stories
- Five stocks we like better than Sunshine Biopharma
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
